FDA permits marketing of first non-drug treatment for ADHD
The device generates a low-level electrical pulse and connects via a wire to a small patch that adheres to a patient’s forehead.
Read More
Tag: ADHD
FDA rejects Sunovion’s ADHD drug
Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators.
Read More
UK children experiencing chronic delays in ADHD diagnosis
Young people in the UK with ADHD are at “serious risk of social and mental health harm” because they experience some of the “longest and most complicated” delays to diagnosis anywhere in Europe, a group of experts is warning.
Read More
Shire’s Intuniv hits targets in adult ADHD trial
Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient group.
Read More
Shire secures US nod for once-daily ADHD drug
Shire has finally bagged approval in the US for its long-acting attention deficit hyperactivity disorder drug (ADHD) Mydayis.
Read More
Shire refiles ADHD drug
Shire has refiled its experimental attention deficit hyperactivity disorder drug SHP 465 in the US, having garnered new data further backing its safety and efficacy.
Read More
Alcobra pulls plug on ADHD drug after PhIII failure
Alcobra’s experimental therapy for the treatment of attention-deficit hyperactivity disorder in adults has failed to hit targets in a late-stage trial, throwing a shadow of doubt over the future of the company.
Read More
Shire to re-file ADHD drug this year
Shire is now gearing up to re-file its attention-deficit hyperactivity drug SHP 465 in the US by the end of this year, on the back of new data further backing its safety and efficacy.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
